analyzátor biochemický biolis 50i superior
tokyo boeki machinery ltd. 2-13-8 hatchobori, chuo-ku tokyo japonsko -
gél s kyselinou hyalurónovou aliaxin sv (superior volume)
rose pharma sa via san gottardo 10 6900 lugano Švajčiarsko -
comirnaty
biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcíny - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. použitie tejto vakcíny by mali byť v súlade s oficiálne odporúčania.
letybo 50 jednotiek prášok na injekčný roztok
croma-pharma gmbh , rakúsko - botulotoxín - 63 - myorelaxantia
dysport 500 u
ipsen pharma, francúzsko - botulotoxín - 63 - myorelaxantia
dysport 300 u
ipsen pharma, francúzsko - botulotoxín - 63 - myorelaxantia
oxsoralen
g.l. pharma gmbh, rakúsko - metoxsalén - 42 - chemotherapeutica (vratane tuberkulostatik)
vistabel
abbvie s.r.o., slovensko - botulotoxín - 63 - myorelaxantia
nuceiva
evolus pharma b.v. - botulotoxín typu a - starnutie pokožky - iných prostriedkov na uvoľňovanie svalov, okrajovo agentov konajúcich - dočasné zlepšenie vzhľadu stredne ťažké až ťažké vertikálne čiary medzi obočím vidieť na maximálne mračiť (glabelárnej riadkov), keď závažnosti nad tváre linky má dôležitý psychologický vplyv u dospelých ľudí pod 65 rokov.
atectura breezhaler
novartis europharm limited - indacaterol acetate, mometasone furoate - astma - drogy obštrukčnej choroby dýchacích ciest, - atectura breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.